Sanofi SA

03/26/2022 | Press release | Distributed by Public on 03/26/2022 10:25

Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis